Nurix Therapeutics Inc. (NASDAQ: NRIX) reported a net loss of $87.2 million, or $0.79 per share, for the quarter ended February 28, 2026, compared to a net loss of $56.4 million, or $0.67 per share, in the same period last year, according to a company statement.

The clinical-stage biopharmaceutical company's revenue declined to $6.3 million from $18.5 million in the prior-year quarter, primarily due to decreased collaboration revenue from Sanofi as the initial research term for certain drug targets ended.

Research and development expenses increased to $84.1 million from $69.7 million, driven by higher compensation costs, clinical expenses, and contract manufacturing costs related to the company's ongoing Phase 2 trial of bexobrutideg. General and administrative expenses rose to $14.6 million from $11.7 million.

Cash, cash equivalents, and marketable securities totaled $540.7 million as of February 28, 2026, down from $592.9 million at November 30, 2025.

The company is enrolling patients in its DAYBreak CLL-201 pivotal Phase 2 study of bexobrutideg for relapsed/refractory chronic lymphocytic leukemia, designed to support accelerated approval. Nurix plans to initiate a global randomized Phase 3 confirmatory trial by mid-2026.

Nurix is also conducting a Phase 1 study evaluating a new tablet formulation of bexobrutideg to support an investigational new drug filing for immunology and inflammation indications in 2026. The company continues advancing partnered programs including STAT6 degrader development with Sanofi and IRAK4 degrader trials with Gilead.